These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 1951408)
1. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Paladino JA; Sperry HE; Backes JM; Gelber JA; Serrianne DJ; Cumbo TJ; Schentag JJ Am J Med; 1991 Nov; 91(5):462-70. PubMed ID: 1951408 [TBL] [Abstract][Full Text] [Related]
2. Clinical and economic impact of oral ciprofloxacin as follow-up to parenteral antibiotics. Grasela TH; Paladino JA; Schentag JJ; Huepenbecker D; Rybacki J; Purcell JB; Fiedler JB DICP; 1991; 25(7-8):857-62. PubMed ID: 1949945 [TBL] [Abstract][Full Text] [Related]
3. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. Peacock JE; Pegram PS; Weber SF; Leone PA Am J Med; 1989 Nov; 87(5A):185S-190S. PubMed ID: 2686421 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections. Gallis HA; Brennan RO; Goodwin SD; Swinney V; Rumbaugh MM; Drew RH Am J Med; 1989 Nov; 87(5A):176S-180S. PubMed ID: 2686418 [TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections. Levine DP; McNeil P; Lerner SA Am J Med; 1989 Nov; 87(5A):160S-163S. PubMed ID: 2686416 [TBL] [Abstract][Full Text] [Related]
6. Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis. Amodio-Groton M; Madu A; Madu CN; Briceland LL; Seligman M; McMaster P; Miller MH Ann Pharmacother; 1996 Jun; 30(6):596-602. PubMed ID: 8792944 [TBL] [Abstract][Full Text] [Related]
7. Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections. Balfour JA; Faulds D Pharmacoeconomics; 1993 May; 3(5):398-421. PubMed ID: 10146890 [TBL] [Abstract][Full Text] [Related]
8. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. Fass RJ; Plouffe JF; Russell JA Am J Med; 1989 Nov; 87(5A):164S-168S. PubMed ID: 2589361 [TBL] [Abstract][Full Text] [Related]
9. Treatment of serious infections with intravenous ciprofloxacin. French Multicenter Study Group. Modai J Am J Med; 1989 Nov; 87(5A):243S-247S. PubMed ID: 2686426 [TBL] [Abstract][Full Text] [Related]
10. Oral ciprofloxacin versus intravenous therapy with other non-quinolone agents: a study of 291 infections. Lorian V; Pavletich K Drugs Exp Clin Res; 1994; 20(5):209-14. PubMed ID: 7875058 [TBL] [Abstract][Full Text] [Related]
11. Intravenous ciprofloxacin or ceftazidime in selected infections. A prospective, randomized, controlled study. Villavicencio J; Asensio de Fernandez ME; Ramirez CA Am J Med; 1989 Nov; 87(5A):191S-194S. PubMed ID: 2686422 [TBL] [Abstract][Full Text] [Related]
12. Comparison of sequential intravenous/oral ciprofloxacin plus metronidazole with intravenous ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections. Wacha H; Warren B; Bassaris H; Nikolaidis P; Surg Infect (Larchmt); 2006 Aug; 7(4):341-54. PubMed ID: 16978077 [TBL] [Abstract][Full Text] [Related]
13. Intravenous/oral ciprofloxacin therapy of infections caused by multiresistant bacteria. Neu HC; Davidson S; Briones F Am J Med; 1989 Nov; 87(5A):209S-212S. PubMed ID: 2511758 [TBL] [Abstract][Full Text] [Related]
14. Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding. Sifuentes-Osornio J; MacĂas A; Amieva RI; Ramos A; Ruiz-Palacios GM Am J Med; 1989 Nov; 87(5A):202S-205S. PubMed ID: 2686425 [TBL] [Abstract][Full Text] [Related]
15. Ciprofloxacin (intravenous/oral) versus ceftazidime in lower respiratory tract infections. Haddow A; Greene S; Heinz G; Wantuck D Am J Med; 1989 Nov; 87(5A):113S-115S. PubMed ID: 2686410 [TBL] [Abstract][Full Text] [Related]
16. Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group. Krumpe PE; Cohn S; Garreltes J; Ramirez J; Coulter H; Haverstock D; Echols R J Antimicrob Chemother; 1999 Mar; 43 Suppl A():117-28. PubMed ID: 10225582 [TBL] [Abstract][Full Text] [Related]
17. Sequential intravenous/oral ciprofloxacin as an empiric antimicrobial therapy: results of a Canadian multicenter study. The Canadian Collaborative Investigational Group. Davis C Clin Ther; 1994; 16(3):505-21. PubMed ID: 7923317 [TBL] [Abstract][Full Text] [Related]
18. Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST). Ten Doesschate T; van Mens SP; van Nieuwkoop C; Geerlings SE; Hoepelman AIM; Bonten MJM BMC Infect Dis; 2018 Dec; 18(1):626. PubMed ID: 30518334 [TBL] [Abstract][Full Text] [Related]
19. Oral ciprofloxacin vs parenteral cefotaxime in the treatment of difficult skin and skin structure infections. A multicenter trial. Gentry LO; Ramirez-Ronda CH; Rodriguez-Noriega E; Thadepalli H; del Rosal PL; Ramirez C Arch Intern Med; 1989 Nov; 149(11):2579-83. PubMed ID: 2684078 [TBL] [Abstract][Full Text] [Related]
20. Use of intravenous ciprofloxacin in difficult-to-treat infections. Giamarellou H; Galanakis N Am J Med; 1987 Apr; 82(4A):346-51. PubMed ID: 3555059 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]